Clinical Trial Update: Safety, Pharmacokinetics (PK) of AKT and MEK Combination [Phase 1]

View source ↗

Summary

This Phase 1 trial reports safety and pharmacokinetic data for a combination of an AKT inhibitor and a MEK inhibitor in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AKT inhibitor (AKT inhibitor)
• MEK inhibitor

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED